Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Given Consensus Rating of "Moderate Buy" by Brokerages

Key Points

• Silence Therapeutics has a “Moderate Buy” consensus rating from six analysts: four buys, one strong buy, and one sell. The average 1-year price target is $55.00, with HC Wainwright setting a $75.00 target.
• The stock opened at $11.24, near its 52-week high of $12.19, but the company reported a quarterly loss of $0.32 per share versus the $0.18 expected and revenue of $0.42 million versus estimates of $1.25 million.
• Institutional investors own 98.73% of the company, with several hedge funds and asset managers recently initiating or increasing positions. Silence is developing RNAi therapies including SLN360 for cardiovascular risk reduction and SLN124 for blood disorders.

Shares of Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN - Get Free Report) have received a consensus rating of "Moderate Buy" from the six research firms that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, four have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among analysts that have covered the stock in the last year is $55.00.

Several equities research analysts have recently issued reports on SLN shares. Weiss Ratings restated a "sell (d-)" rating on shares of Silence Therapeutics in a report on Friday, July 17th. Cantor Fitzgerald started coverage on Silence Therapeutics in a research report on Wednesday, June 24th. They set an "overweight" rating on the stock. Finally, HC Wainwright reissued a "buy" rating and issued a $75.00 price target on shares of Silence Therapeutics in a research note on Wednesday, June 17th.

Silence Therapeutics Stock Performance

Shares of NASDAQ SLN opened at $11.24 on Thursday. Silence Therapeutics has a 1 year low of $4.19 and a 1 year high of $12.19. The firm's 50 day moving average price is $9.11 and its 200 day moving average price is $7.08. The firm has a market cap of $530.98 million, a P/E ratio of -7.07 and a beta of 1.39.

Silence Therapeutics (NASDAQ:SLN - Get Free Report) last issued its quarterly earnings results on Friday, May 8th. The company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.14). Silence Therapeutics had a negative net margin of 8,943.86% and a negative return on equity of 105.34%. The business had revenue of $0.42 million during the quarter, compared to analyst estimates of $1.25 million. As a group, equities analysts predict that Silence Therapeutics will post -1.08 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. XTX Topco Ltd purchased a new stake in Silence Therapeutics in the fourth quarter valued at approximately $71,000. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Silence Therapeutics by 65.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 13,653 shares of the company's stock valued at $83,000 after purchasing an additional 5,421 shares during the last quarter. Citadel Advisors LLC acquired a new position in shares of Silence Therapeutics in the 3rd quarter valued at $112,000. Massar Capital Management LP purchased a new stake in shares of Silence Therapeutics during the 2nd quarter valued at $115,000. Finally, GAMMA Investing LLC grew its stake in shares of Silence Therapeutics by 18.1% during the 2nd quarter. GAMMA Investing LLC now owns 11,063 shares of the company's stock valued at $121,000 after buying an additional 1,698 shares during the period. 98.73% of the stock is currently owned by hedge funds and other institutional investors.

About Silence Therapeutics

Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence's technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.

The company's lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source